GlassScriptPhysician profile
Rachael M Murphy
NPI 1528039781
$13,987.98
in general payments reported to CMS, 2019-2025
63 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $1,743 · 2021: $2,584 · 2022: $1,990 · 2023: $1,892 · 2024: $3,106 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,537 · Travel and Lodging: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.65 |
| Travel and Lodging | $1,135.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,711.80 | 2019-2025 | |
| Modernatx, INC. | $1,435.11 | 2024 | |
| Novo Nordisk INC | $1,224.50 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $937.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $758.01 | 2019-2025 | Farxiga, Breztri |
| Sunovion Pharmaceuticals INC. | $744.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $734.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $673.10 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $573.49 | 2020-2025 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.93 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $391.11 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.21 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $342.61 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.46 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Noven Therapeutics, LLC | $271.13 | 2023-2025 | Xelstrym, Secuado |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $259.73 | 2021-2025 | Unithroid |
| Allergan, INC. | $227.55 | 2019-2020 | |
| Axsome Therapeutics, INC. | $220.39 | 2023-2025 | Auvelity |
| Alkermes, INC. | $200.92 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Jazz Pharmaceuticals INC. | $189.14 | 2021-2022 | |
| Tolmar, INC. | $145.53 | 2023-2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $112.98 | 2021-2023 | |
| Horizon Therapeutics Plc | $102.99 | 2020-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $100.27 | 2020-2023 | Spravato |
| Amgen INC. | $99.58 | 2019-2025 | Prolia, Evenity, Repatha |
| Mdd US Operations, LLC | $98.08 | 2019 | |
| Indivior INC. | $95.42 | 2021-2025 | Sublocade |
| Kowa Pharmaceuticals America, INC. | $94.07 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $85.75 | 2022-2023 | Quviviq |
| Intra-Sana Laboratories | $82.92 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Shield Therapeutics INC | $70.77 | 2023-2025 | Accrufer |
| Boston Scientific Corporation | $62.84 | 2022-2024 | |
| Gilead Sciences, INC. | $59.09 | 2020-2021 | |
| Eisai INC. | $55.53 | 2021-2022 | |
| Alfasigma USA, INC. | $48.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $39.16 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $37.78 | 2022 | |
| Orexo US, INC. | $35.63 | 2021 | |
| Genzyme Corporation | $35.51 | 2025 | |
| Kyowa Kirin, INC. | $35.39 | 2023-2025 | Crysvita |
| Acerus Pharmaceuticals Corporation | $35.34 | 2021 | |
| Abbott Laboratories | $32.71 | 2021-2022 | |
| Corcept Therapeutics | $32.66 | 2021 | |
| Sumitomo Pharma America, INC. | $29.99 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $26.27 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $23.60 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $22.03 | 2024 | (5050) Extended Holter |
| Smith+Nephew, INC. | $21.45 | 2025 | Collagenase Santyl |
| Biohaven Pharmaceutical Holding Company LTD. | $21.16 | 2022 | |
| Antares Pharma, INC. | $20.99 | 2023 | Tlando, Xyosted, Nocdurna |
| Shire North American Group INC | $20.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.99 | 2025 | Relexxii |
| Lundbeck LLC | $19.31 | 2024 | Rexulti |
| Renalytix Ai, INC. | $19.31 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Adlon Therapeutics L.P. | $18.28 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.34 | 2020 | |
| Qiagen, LLC | $16.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.11 | 2024 | Voquezna |
| Acella Pharmaceuticals, LLC | $14.52 | 2025 | NP Thyroid 60 |
| Almirall LLC | $11.07 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$101,737.19 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.